Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May:149:102-104.
doi: 10.1016/j.ejca.2021.01.056. Epub 2021 Mar 20.

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

F X Danlos  1 , F Ackermann  2 , J Rohmer  2 , M Roumier  2 , A Marabelle  3 , J M Michot  4
Affiliations
Comment

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

F X Danlos et al. Eur J Cancer. 2021 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
TNF-α levels were measured in serum collected from Healthy controls and COVID-19 patients before ‘baseline’ and 7 days after tocilizumab. Data shown are those of all the patients treated with tocilizumab and who were able to provide a pre-treatment (baseline) and post-treatment serum (up-to-date serum +7). Of the 25 patients treated with tocilizumab, pre-treatment and post-treatment serum analyses were available for 18 patients represented according to their outcome; mortality before day 30 (left panel) and response to tocilizumab (right panel). Baseline TNF-α serum levels were significantly higher at baseline in patients who eventually died of Covid19 (left panel). Post-tocilizumab TNF-α serum levels were significantly increasing in patients who did not favourably respond to tocilizumab (right panel).
See this image and copyright information in PMC

Comment on

References

    1. Feldmann M., Maini R.N., Woody J.N., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407–1409. - PMC - PubMed
    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. McGonagle D., O'Donnell J.S., Sharif K., Emery P., Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2:e437–e445. - PMC - PubMed
    1. Guaraldi G., Meschiari M., Cozzi-Lepri A., et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–e484. - PMC - PubMed
    1. Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975. - PMC - PubMed

Substances